• Normalised EBIT up 18.7% to $582.9m
• Normalised NPAT up 19.2% to $392.0m
• Revenue up 14.9% to $5.5bn

Sigma Healthcare Limited (Sigma) today announced its results for the half year ended 31 December 2025 (1H26), delivering strong financial performance, continued expansion of the Chemist Warehouse (CW) branded network in both domestic and international markets, and solid progress on integration and synergy delivery. Key highlights include: Normalised EBIT of $582.9m, up 18.7% on the prior corresponding period (pcp); Normalised NPAT of $392.0m, up 19.2% on pcp; Revenue of $5.5bn, up 14.9% on pcp. Performance was driven by Australian CW branded store sales up 17.2% with like-for-like (LFL) sales up 15.0%, and international growth accelerating with retail network sales up 24.5% and LFL sales up 11.1%. The company has completed the conversion of the MyChemist franchise stores to Amcal and DDS franchises, and plans to onboard 15 Amcal stores in 2H26. Sigma's supply chain continues to demonstrate the benefits of scale and volume, with over 298 million units distributed during the half, up 5.1% on the pcp. The company is progressing integration with discipline, delivering $13.0 million in early synergies in this half and laying the foundations for the full $100 million per annum synergy target to be achieved by FY29.

Year to date trading including the first seven weeks of the second half has seen growth momentum continue, with Australian CW branded store sales up 16.6% and LFL sales up 14.4%.

With solid trading momentum, and synergy benefits still ahead of us, Sigma is well positioned to deliver sustained growth and long-term shareholder value.